Abstract IA11: Molecular targeted therapies for advanced HCC

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. Current major advancements have impacted the management of patients with advanced HCC substantially improving their life expectancy. Several systemic therapies have resulted in positive III investigations (atezolizumab plus bevacizumab, durvalumab plus tremelimumab, sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab) and two additional therapies obtained accelerated FDA approval owing to evidence of efficacy (pembrolizumab and nivolumab plus ipilimumab). Specifically, among TKIs, sorafenib and lenvatininb remain as first line option therapies in patients with contraindications or upon progression to immunotherapies. In second-line, regorafenib, cabozantinib and ramucirumab are the accepted choices. Few studies suggest that biomarkers or treatment related-AEs are associated with better outcome, as it is the case with hand-foot skin reaction with sorafenib, or AFP> 400 ng/ml or hypertension for ramucirumab. The fact that most HCC do not have a dominant actionable target has prevented precision oncology. Nonetheless, current studies are exploring abrogating main drivers previously unactionable, such as wnt signaling. The fact that TKI and VEGF-based MAb have also immunomodulatory activities has boosted their combination with immune therapies which nowadays are dominant in the landscape of management of HCC and ongoing phase III trials. Citation Format: Josep M. Llovet. Molecular targeted therapies for advanced HCC [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr IA11.